This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Click here for VELSIPITY▼ (etrasimod) Prescribing Information. Adverse event reporting can be found at the bottom of the page.

Home

Menu

Close

Unmet NeedEfficacyEfficacy Home PageTrial DesignClinical RemissionEndoscopic ImprovementCorticosteroid-Free RemissionIsolated ProctitisBio/JAKi Subgroups DataInduction RespondersSymptomatic ResponseBowel UrgencySafetyAdverse eventsPooled and Interim Safety DataSpecial Warnings and PrecautionsCardiac and Ocular Adverse ReactionsGetting StartedGetting StartedContraindications and Interactions

Pre-first Dose Testing
ResourcesEventsMaterialsVideos

VELSIPITY is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.1

Clinical Remission

ELEVATE UC 52

ELEVATE UC 12

Tab Number 3

Tab Number 4

Tab Number 5

VELSIPITY helped patients calm their UC symptoms 

Significant and sustained clinical remission* vs placebo in ELEVATE UC 521

2 out of 3 patients who achieved clinical remission with VELSIPITY at Week 12, also sustained it at 
Week 52, regardless of concomitant steroid use‡2

*Clinical remission was defined as a stool frequency subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal 
bleeding subscore of 0, and an endoscopy score ≤1 (excluding friability).
†Corticosteroid-free remission was defined as remission at Week 52 without receiving corticosteroids for ≥12 weeks 
immediately prior to Week 52.
‡Sustained clinical remission was defined as clinical remission at both Week 12 and Week 52, and was achieved by 49 patients (out of 274), corresponding to approximately 66% of patients who achieved clinical remission at Week 12 (n=74/274).1
Investigators were directed to taper corticosteroids in ELEVATE UC 52 after the Week 12 assessment.2
ReferencesEndoscopic improvementSee how patients may achieve 
endoscopic improvement with VELSIPITY 
vs placebo.
SEE ENDOSCOPIC IMPROVEMENT
Loading
CI – confidence interval; UC – ulcerative colitis.References:VELSIPITY Summary of Product Characteristics.Sandborn WJ et al. Lancet 2023;401(10383):1159-1171.
VELSIPITY helped patients calm UC symptoms vs placebo

Significant clinical remission* vs placebo in ELEVATE UC 121

ReferencesClinical remission was defined as a stool frequency subscore of 0 (or of 1 with a ≥1-point decrease from baseline), a rectal bleeding subscore of 0, and an endoscopy score ≤1 (excluding friability).1Endoscopic improvementSee how patients may achieve 
endoscopic improvement with VELSIPITY 
vs placebo.
SEE ENDOSCOPIC IMPROVEMENT
Loading

CI – confidence interval; UC – ulcerative colitis.References:VELSIPITY Summary of Product Characteristics. 
Efficacy
PP-V1A-GBR-0020. August 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​

You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​